| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
|
N Engl J Med
|
2005
|
28.99
|
|
2
|
The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity.
|
Am J Psychiatry
|
2008
|
9.00
|
|
3
|
Persistent cannabis users show neuropsychological decline from childhood to midlife.
|
Proc Natl Acad Sci U S A
|
2012
|
5.67
|
|
4
|
A genome-wide investigation of SNPs and CNVs in schizophrenia.
|
PLoS Genet
|
2009
|
5.01
|
|
5
|
A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia.
|
Schizophr Bull
|
2005
|
4.66
|
|
6
|
Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria.
|
Biol Psychiatry
|
2004
|
4.46
|
|
7
|
Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment.
|
Am J Psychiatry
|
2006
|
4.12
|
|
8
|
The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization.
|
Am J Psychiatry
|
2008
|
4.02
|
|
9
|
Cognition in schizophrenia: summary Nice Consultation Meeting 2012.
|
Eur Neuropsychopharmacol
|
2013
|
3.99
|
|
10
|
Antipsychotic drug effects on brain morphology in first-episode psychosis.
|
Arch Gen Psychiatry
|
2005
|
3.78
|
|
11
|
Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia.
|
Am J Psychiatry
|
2006
|
3.72
|
|
12
|
Functional co-primary measures for clinical trials in schizophrenia: results from the MATRICS Psychometric and Standardization Study.
|
Am J Psychiatry
|
2008
|
3.29
|
|
13
|
Schizophrenia is a cognitive illness: time for a change in focus.
|
JAMA Psychiatry
|
2013
|
3.16
|
|
14
|
Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic.
|
Am J Psychiatry
|
2006
|
3.12
|
|
15
|
Static and dynamic cognitive deficits in childhood preceding adult schizophrenia: a 30-year study.
|
Am J Psychiatry
|
2010
|
3.05
|
|
16
|
Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study.
|
Am J Psychiatry
|
2007
|
2.75
|
|
17
|
Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study.
|
Am J Psychiatry
|
2007
|
2.68
|
|
18
|
Neuropsychology of the prodrome to psychosis in the NAPLS consortium: relationship to family history and conversion to psychosis.
|
Arch Gen Psychiatry
|
2010
|
2.54
|
|
19
|
Neuropsychological decline in schizophrenia from the premorbid to the postonset period: evidence from a population-representative longitudinal study.
|
Am J Psychiatry
|
2014
|
2.51
|
|
20
|
Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: outcomes from CATIE-AD.
|
Am J Psychiatry
|
2011
|
2.15
|
|
21
|
A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia.
|
Biol Psychiatry
|
2010
|
1.99
|
|
22
|
Etiological and clinical features of childhood psychotic symptoms: results from a birth cohort.
|
Arch Gen Psychiatry
|
2010
|
1.85
|
|
23
|
Neuropsychological impairments in schizophrenia and psychotic bipolar disorder: findings from the Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP) study.
|
Am J Psychiatry
|
2013
|
1.85
|
|
24
|
Relationship of cognition and psychopathology to functional impairment in schizophrenia.
|
Am J Psychiatry
|
2008
|
1.62
|
|
25
|
What CATIE found: results from the schizophrenia trial.
|
Psychiatr Serv
|
2008
|
1.55
|
|
26
|
Microvascular abnormality in schizophrenia as shown by retinal imaging.
|
Am J Psychiatry
|
2013
|
1.53
|
|
27
|
Preserved working memory and altered brain activation in persons at risk for psychosis.
|
Am J Psychiatry
|
2013
|
1.52
|
|
28
|
The MCCB impairment profile for schizophrenia outpatients: results from the MATRICS psychometric and standardization study.
|
Schizophr Res
|
2010
|
1.43
|
|
29
|
Pharmacogenetics of antipsychotic response in the CATIE trial: a candidate gene analysis.
|
Eur J Hum Genet
|
2009
|
1.38
|
|
30
|
Extrapyramidal side-effects of antipsychotics in a randomised trial.
|
Br J Psychiatry
|
2008
|
1.37
|
|
31
|
The FDA-NIMH-MATRICS guidelines for clinical trial design of cognitive-enhancing drugs: what do we know 5 years later?
|
Schizophr Bull
|
2010
|
1.36
|
|
32
|
Cognitive functioning in schizophrenia: a consensus statement on its role in the definition and evaluation of effective treatments for the illness.
|
J Clin Psychiatry
|
2004
|
1.33
|
|
33
|
The Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndrome.
|
Schizophr Res
|
2005
|
1.28
|
|
34
|
Methodological issues in negative symptom trials.
|
Schizophr Bull
|
2011
|
1.28
|
|
35
|
Proof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophrenia.
|
Neuropsychopharmacology
|
2009
|
1.28
|
|
36
|
Results of phase 3 of the CATIE schizophrenia trial.
|
Schizophr Res
|
2008
|
1.23
|
|
37
|
Neuropsychological course in the prodrome and first episode of psychosis: findings from the PRIME North America Double Blind Treatment Study.
|
Schizophr Res
|
2008
|
1.20
|
|
38
|
Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial.
|
Schizophr Res
|
2005
|
1.20
|
|
39
|
Genome-wide pharmacogenomic study of neurocognition as an indicator of antipsychotic treatment response in schizophrenia.
|
Neuropsychopharmacology
|
2010
|
1.19
|
|
40
|
Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia.
|
Schizophr Res
|
2011
|
1.17
|
|
41
|
The Cognitive Assessment Interview (CAI): development and validation of an empirically derived, brief interview-based measure of cognition.
|
Schizophr Res
|
2010
|
1.15
|
|
42
|
Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs. ziprasidone.
|
Schizophr Res
|
2011
|
1.14
|
|
43
|
Circumstances under which practice does not make perfect: a review of the practice effect literature in schizophrenia and its relevance to clinical treatment studies.
|
Neuropsychopharmacology
|
2010
|
1.13
|
|
44
|
NCAM1 and neurocognition in schizophrenia.
|
Biol Psychiatry
|
2006
|
1.10
|
|
45
|
Abbreviated neuropsychological assessment in schizophrenia: prediction of different aspects of outcome.
|
J Clin Exp Neuropsychol
|
2009
|
1.10
|
|
46
|
Bifactor and item response theory analyses of interviewer report scales of cognitive impairment in schizophrenia.
|
Psychol Assess
|
2011
|
1.05
|
|
47
|
Baseline use of concomitant psychotropic medications to treat schizophrenia in the CATIE trial.
|
Psychiatr Serv
|
2006
|
1.05
|
|
48
|
The effects of antipsychotic medications on emotion perception in patients with chronic schizophrenia in the CATIE trial.
|
Schizophr Res
|
2009
|
1.04
|
|
49
|
Measuring outcome priorities and preferences in people with schizophrenia.
|
Br J Psychiatry
|
2005
|
1.03
|
|
50
|
Development and psychometric performance of the schizophrenia objective functioning instrument: an interviewer administered measure of function.
|
Schizophr Res
|
2008
|
0.99
|
|
51
|
The neuregulin 1 promoter polymorphism rs6994992 is not associated with chronic schizophrenia or neurocognition.
|
Am J Med Genet B Neuropsychiatr Genet
|
2008
|
0.97
|
|
52
|
Efficiency of the CATIE and BACS neuropsychological batteries in assessing cognitive effects of antipsychotic treatments in schizophrenia.
|
J Int Neuropsychol Soc
|
2008
|
0.96
|
|
53
|
Cognition as an outcome measure in schizophrenia.
|
Br J Psychiatry Suppl
|
2007
|
0.95
|
|
54
|
Dopamine D2 receptor occupancy and cognition in schizophrenia: analysis of the CATIE data.
|
Schizophr Bull
|
2012
|
0.94
|
|
55
|
Insight in first-episode psychosis.
|
Psychol Med
|
2006
|
0.94
|
|
56
|
Anticipating DSM-V: opportunities and challenges for cognition and psychosis.
|
Schizophr Bull
|
2009
|
0.94
|
|
57
|
A brief cognitive assessment tool for schizophrenia: construction of a tool for clinicians.
|
Schizophr Bull
|
2009
|
0.94
|
|
58
|
The Cognitive Assessment Interview (CAI): reliability and validity of a brief interview-based measure of cognition.
|
Schizophr Bull
|
2012
|
0.93
|
|
59
|
Longitudinal consent-related abilities among research participants with schizophrenia: results from the CATIE study.
|
Schizophr Res
|
2011
|
0.91
|
|
60
|
Substance use and schizophrenia: adverse correlates in the CATIE study sample.
|
Schizophr Res
|
2011
|
0.89
|
|
61
|
Memory-prediction errors and their consequences in schizophrenia.
|
Neuropsychol Rev
|
2009
|
0.89
|
|
62
|
Risperidone and cognitive function in children with disruptive behavior disorders.
|
Biol Psychiatry
|
2007
|
0.87
|
|
63
|
Armodafinil as adjunctive therapy in adults with cognitive deficits associated with schizophrenia: a 4-week, double-blind, placebo-controlled study.
|
J Clin Psychiatry
|
2010
|
0.87
|
|
64
|
Validation of the French version of the BACS (the brief assessment of cognition in schizophrenia) among 50 French schizophrenic patients.
|
Eur Psychiatry
|
2007
|
0.86
|
|
65
|
AKT1 and neurocognition in schizophrenia.
|
Aust N Z J Psychiatry
|
2007
|
0.86
|
|
66
|
The Longitudinal Youth at Risk Study (LYRIKS)--an Asian UHR perspective.
|
Schizophr Res
|
2013
|
0.85
|
|
67
|
Optimization of a multinomial model for investigating hallucinations and delusions with source monitoring.
|
Schizophr Res
|
2006
|
0.84
|
|
68
|
Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia.
|
J Clin Psychiatry
|
2010
|
0.82
|
|
69
|
Standardizing the use of the Continuous Performance Test in schizophrenia research: a validation study.
|
Schizophr Res
|
2012
|
0.82
|
|
70
|
Issues and perspectives in designing clinical trials for negative symptoms in schizophrenia.
|
Schizophr Res
|
2013
|
0.82
|
|
71
|
Validation of the Persian version of the brief assessment of cognition in schizophrenia in patients with schizophrenia and healthy controls.
|
Psychiatry Clin Neurosci
|
2013
|
0.82
|
|
72
|
The course of cognitive functioning over six months in individuals at clinical high risk for psychosis.
|
Psychiatry Res
|
2012
|
0.81
|
|
73
|
Proof-of-concept randomized controlled trial of pregnenolone in schizophrenia.
|
Psychopharmacology (Berl)
|
2014
|
0.81
|
|
74
|
The Schizophrenia Cognition Rating Scale: validation of an interview-based assessment of cognitive functioning in Asian patients with schizophrenia.
|
Psychiatry Res
|
2010
|
0.81
|
|
75
|
Differential effects of emotional information on interference task performance across the life span.
|
Front Aging Neurosci
|
2010
|
0.81
|
|
76
|
No association of the serotonin transporter polymorphisms 5-HTTLPR and RS25531 with schizophrenia or neurocognition.
|
Am J Med Genet B Neuropsychiatr Genet
|
2010
|
0.80
|
|
77
|
Adjunctive Minocycline in Clozapine-Treated Schizophrenia Patients With Persistent Symptoms.
|
J Clin Psychopharmacol
|
2015
|
0.80
|
|
78
|
A randomized controlled trial of allopurinol vs. placebo added on to antipsychotics in patients with schizophrenia or schizoaffective disorder.
|
Schizophr Res
|
2012
|
0.79
|
|
79
|
Sensory acuity and reasoning in delusional disorder.
|
Compr Psychiatry
|
2002
|
0.79
|
|
80
|
Employment outcomes in a randomized trial of second-generation antipsychotics and perphenazine in the treatment of individuals with schizophrenia.
|
J Behav Health Serv Res
|
2008
|
0.78
|
|
81
|
Unraveling the relationship between obesity, schizophrenia and cognition.
|
Schizophr Res
|
2013
|
0.78
|
|
82
|
Formulation of the age-education index: measuring age and education effects in neuropsychological performance.
|
Psychol Assess
|
2012
|
0.78
|
|
83
|
Validation of a clinician questionnaire to assess reasons for antipsychotic discontinuation and continuation among patients with schizophrenia.
|
Psychiatry Res
|
2012
|
0.78
|
|
84
|
Applicability of the MATRICS Consensus Cognitive Battery in Singapore.
|
Clin Neuropsychol
|
2013
|
0.78
|
|
85
|
Social cognition as a mediator between neurocognition and functional outcome in individuals at clinical high risk for psychosis.
|
Schizophr Res
|
2013
|
0.77
|
|
86
|
Comprehensive model of how reality distortion and symptoms occur in schizophrenia: could impairment in learning-dependent predictive perception account for the manifestations of schizophrenia?
|
Psychiatry Clin Neurosci
|
2011
|
0.77
|
|
87
|
Methods for delivering and evaluating the efficacy of cognitive enhancement.
|
Handb Exp Pharmacol
|
2015
|
0.77
|
|
88
|
Cognition and schizophrenia: is there a role for cognitive assessments in diagnosis and treatment?
|
Psychiatry (Edgmont)
|
2008
|
0.76
|
|
89
|
Observable Social Cognition--A Rating Scale: an interview-based assessment for schizophrenia.
|
Cogn Neuropsychiatry
|
2015
|
0.76
|
|
90
|
CMINDS does not have identical tests to the CATIE and MATRICS batteries. Commentary on O'Halloran et al.
|
Schizophr Res
|
2008
|
0.76
|
|
91
|
Clues to the cognitive and perceptual origins of social isolation and psychosis in schizophrenia.
|
Am J Psychiatry
|
2012
|
0.76
|
|
92
|
The Singapore flagship programme in translational and clinical research in psychosis.
|
Early Interv Psychiatry
|
2011
|
0.76
|
|
93
|
Interview-based assessment of cognition in schizophrenia: applicability of the Schizophrenia Cognition Rating Scale (SCoRS) in different phases of illness and settings of care.
|
Schizophr Res
|
2013
|
0.75
|
|
94
|
Criminal justice system involvement among people with schizophrenia.
|
Community Ment Health J
|
2010
|
0.75
|
|
95
|
How specific are negative symptoms and cognitive impairment in schizophrenia? An analysis of PANSS and SCoRS.
|
Cogn Neuropsychiatry
|
2012
|
0.75
|
|
96
|
The Impact of Medication Anticholinergic Burden on Cognitive Performance in People With Schizophrenia.
|
J Clin Psychopharmacol
|
2017
|
0.75
|
|
97
|
Brief assessment of cognition in schizophrenia: normative data in an English-speaking ethnic Chinese sample.
|
Arch Clin Neuropsychol
|
2013
|
0.75
|